ライフサイエンスコーパス: tetradecanoyl

1 ould also be seen in cells treated with 12-O-tetradecanoyl-1-phorbol-13-acetate (TPA), indicating tha

2 cifically of PKC alpha upon exposure to 12-O-tetradecanoyl-1-phorbol-13-acetate (TPA).

3 t-negative c-Jun (TAM67) inhibits phorbol 12-tetradecanoyl-13-acetate (TPA)-induced AP-1 transactivat

4 12-O-tetradecanoyl-13-acetate (TPA)-responsive gene promoter

5 Moreover, JunD.FosB binds to the 12-O-tetradecanoyl-13-acetate-responsive gene promoter elemen

6 7BL/6 mice nor Nf1+/- mice treated with 12-O-tetradecanoyl-13-acetylphorbol alone.

7 nz-anthracene and/or the tumor promoter 12-O-tetradecanoyl-13-acetylphorbol on mice heterozygous for

8 After exposure to 12-O-tetradecanoyl-13-acetylphorbol, Nf1+/- keratinocytes sho

9 gulate the response of keratinocytes to 12-O-tetradecanoyl-13-acetylphorbol.

10 eatment with dimethylbenzanthracene and 12-O-tetradecanoyl-13-acetylphorbol; papillomas did not devel

11 tion and down-regulation on exposure to 12-O-tetradecanoyl-13-phorbol acetate (TPA).

12 transcription factor AP-1 acting on the 12-O-tetradecanoyl-13-phorbol-acetate-responsive element (TRE

13 alpha showed that only the threo-isomer, 5-O-tetradecanoyl-2,3-dideoxy-L-threo-hexono-1,4-lactone (2)

14 with tetradecanoyl vinyl ester to afford 6-O-tetradecanoyl-alpha-d-cholesteryl glucopyranoside (alpha

15 NN304 [Lys(B29)-tetradecanoyl des(B30) human insulin] is a potentially t

16 fatty acid acylated insulin analog Lys(B29)-tetradecanoyl des-(B30) human insulin, or NN304, as a ma

17 d only two major signals, N-(3-hydroxy-7-cis)tetradecanoyl homoserine lactone [(3-OH)C(14:1)HSL] and

18 increased sensitivities to pentanoyl-HSL and tetradecanoyl-HSL, while maintaining a wild-type or grea

19 N-3-oxo-tetradecanoyl-l-homoserine lactone (oxo-C14-HSL) primed

20 nal methyl ester and a 12-oxo- or 12-hydroxy-tetradecanoyl moiety.

21 lation of LPL, we studied the effect of 12-O-tetradecanoyl phorbol 13-acetate (TPA) on adipocytes.

22 l types, treatment with the PKC activator 12-tetradecanoyl phorbol 13-acetate (TPA) or adhesion to fi

23 of the protein kinase C (PKC) activator, 12-tetradecanoyl phorbol 13-acetate (TPA) or calcium ionoph

24 of fibroblasts with the phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA), specifically inh

25 BA), followed by repeated treatments of 12-O-tetradecanoyl phorbol 13-acetate (TPA).

26 carcinoma BeWo cells, the PKC activator 12-O-tetradecanoyl phorbol 13-acetate and PKC inhibitor bisin

27 of GGAATG core enhancer activity after 12-O-tetradecanoyl phorbol 13-acetate treatment.

28 We also examined the effects of tetradecanoyl phorbol acetate (TPA) and 5-aza-2'-deoxycy

29 ion lymphoma (PEL) cells, but treatment with tetradecanoyl phorbol acetate (TPA) can trigger the full

30 an occur by treatment with the phorbol ester tetradecanoyl phorbol acetate (TPA) or with the transfec

31 uppressed KSHV lytic reactivation induced by tetradecanoyl phorbol acetate (TPA) stimulation, but not

32 ytic cycle induction that can be enhanced by tetradecanoyl phorbol acetate (TPA) treatment.

33 uced infectious virions after induction with tetradecanoyl phorbol acetate (TPA) were rescued in Esch

34 After low-dose application of tetradecanoyl phorbol acetate (TPA), a marked increase i

35 The phorbol ester tetradecanoyl phorbol acetate (TPA), a PKC agonist, is o

36 enzyme, COX-1 and COX-2, their regulation by tetradecanoyl phorbol acetate (TPA), and the associated

37 rs, tumor necrosis factor alpha (TNF-alpha), tetradecanoyl phorbol acetate (TPA), and trichostatin A

38 Like stimulation with tetradecanoyl phorbol acetate (TPA), the ectopic express

39 anti-IgG, and in Raji cells, in response to tetradecanoyl phorbol acetate (TPA), was also inhibited

40 Tetradecanoyl phorbol acetate (TPA)-induced CD44 cleavag

41 Finally, in an in vivo mouse model of tetradecanoyl phorbol acetate (TPA)-induced dermatitis,

42 mally to megakaryocytes after induction with tetradecanoyl phorbol acetate (TPA).

43 nd late-gene expression by the phorbol ester tetradecanoyl phorbol acetate (TPA).

44 Phorbol ester (tetradecanoyl phorbol acetate [TPA]) treatment of latent

45 Tetradecanoyl phorbol acetate and butyrate upregulated K

46 tant for induction of lytic EBV infection by tetradecanoyl phorbol acetate and surface immunoglobulin

47 ein expression either through treatment with tetradecanoyl phorbol acetate in D98/HR1 cells or throug

48 lemented in cells that had been treated with tetradecanoyl phorbol acetate or tumor necrosis factor t

49 rs tested thus far, LANAp is not affected by tetradecanoyl phorbol acetate or viral lytic cycle funct

50 its expression was significantly induced by tetradecanoyl phorbol acetate stimulation.

51 The addition of tetradecanoyl phorbol acetate to KSHV-infected 293 cells

52 se inhibitory effects could be overridden by tetradecanoyl phorbol acetate treatment, indicating that

53 gically significant concentrations following tetradecanoyl phorbol acetate treatment, which induces p

54 n can be induced, however, by treatment with tetradecanoyl phorbol acetate, which mimics EDNRB signal

55 MP-1 is stable, with a half-life of >20 h in tetradecanoyl phorbol acetate- and butyrate-treated B95-

56 ovo primary infection and after spontaneous, tetradecanoyl phorbol acetate-, or open reading frame 50

57 xyuridine into newly synthesized DNA in both tetradecanoyl phorbol acetate-induced JSC-1 primary effu

58 rnatant virions derived from three different tetradecanoyl phorbol acetate-induced PEL cell lines can

59 matin immunoprecipitation (ChIP) assays with tetradecanoyl phorbol acetate-induced PEL cells, RAP pro

60 all associate with RTA promoter sequences in tetradecanoyl phorbol acetate-induced primary effusion l

61 Treatment with MTX completely prevented tetradecanoyl phorbol acetate-induced viral DNA replicat

62 ne transcription in vivo, as directed from a tetradecanoyl phorbol acetate-inducible promoter.

63 ants exhibited a 40- to 180-fold increase in tetradecanoyl phorbol acetate-ionomycin-induced expressi

64 and that, when C/EBPalpha was removed from a tetradecanoyl phorbol acetate-treated JSC-1 primary effu

65 In tetradecanoyl phorbol acetate-treated P3HR1 cultures and

66 In tetradecanoyl phorbol acetate-treated PEL cells, loss of

67 ously expressed in BCBL-1 cells treated with tetradecanoyl phorbol acetate.

68 ly, induction of the virus lytic cycle using tetradecanoyl phorbol acetate/n-butyrate resulted in no

69 orescence and confirmed by immunoblots using tetradecanoyl phorbol ester acetate-induced BC-3 cell ex

70 to the protein kinase C (PKC) activator 12-O-tetradecanoyl phorbol-13-acetate (PMA).

71 c treatment, offspring received topical 12-O-tetradecanoyl phorbol-13-acetate (TPA) through adulthood

72 keratinocytes treated with calcium and 12-O-tetradecanoyl phorbol-13-acetate (TPA), two agents that

73 nduced by tumor promoting drugs such as 12-O-tetradecanoyl phorbol-13-acetate (TPA).

74 sic fibroblast growth factor (bFGF) and 12-O-tetradecanoyl phorbol-13-acetate (TPA).

75 FN-alpha-response by the PKC activator, 12-O-tetradecanoyl phorbol-13-acetate (TPA).

76 ith PEITC-NAC alone; cells treated with 12-O-tetradecanoyl phorbol-13-acetate alone showed active cel

77 KC (cPKC) by pretreatment of cells with 12-O-tetradecanoyl phorbol-13-acetate cannot block UVB-induce

78 inhibitors) in the acquisition of TPA (12-O-tetradecanoyl phorbol-13-acetate)-independent growth in

79 atopoietic cells by treatment with TPA (12-O-tetradecanoyl phorbol-13-acetate).

80 activity was significantly activated by 1-O-tetradecanoyl phorbol-13-acetate, a c-jun activator, and

81 ls that were pretreated with 100 nmol/L 12-O-tetradecanoyl phorbol-13-acetate, and then treated with

82 irradiated HL60 cells but unaffected by 12-O-tetradecanoyl phorbol-13-acetate, forskolin, or cyclospo

83 the PAF effect but not that induced by 12-O-tetradecanoyl phorbol-13-acetate, indicating the specifi

84 UVB-induced AP-1 activity, it can block 12-O-tetradecanoyl phorbol-13-acetate-induced AP-1 activity.

85 lowing starvation and/or treatment with 12-O-tetradecanoyl phorbol-13-acetate.

86 not prevent ERK-2 activation induced by 12-O-tetradecanoyl-phorbol 13-acetate (TPA).

87 ment with dimethyl benzanthracene (DMBA) and tetradecanoyl-phorbol acetate (TPA).

88 s in vivo acute inflammation induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and arachidonic a

89 of these genes and apoptosis induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in several human

90 infected LCLs with the chemical inducer 12-O-tetradecanoyl-phorbol-13-acetate (TPA) led to much great

91 atinocyte differentiation, specifically 12-0-tetradecanoyl-phorbol-13-acetate (TPA) plus ionomycin, T

92 Treatment of mouse skin with 12-0-tetradecanoyl-phorbol-13-acetate (TPA) produced a large

93 pical application of the tumor promotor 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was observed in a

94 Cells treated with 12-O-tetradecanoyl-phorbol-13-acetate (TPA), known to stimula

95 of human tumour cell lines with serum, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), or okadaic acid

96 ication of Lupeol to CD-1 mouse against 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced conventio

97 siRNA knockdown of BLIMP1 inhibited 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced lytic rea

98 f 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced squamous

99 nhanced AP-1 activity when treated with 12-0-tetradecanoyl-phorbol-13-acetate (TPA).

100 n of GLUT1 induced by the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA).

101 nt of these double transgenic mice with 12-O-tetradecanoyl-phorbol-13-acetate caused rapid migration

102 r-promoting 7,12-dimethylbenzanthracene/12-O-tetradecanoyl-phorbol-13-acetate induction.

103 However, in the presence of 12-O-tetradecanoyl-phorbol-13-acetate or forskolin, 10 mM glu

104 lenge by 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoyl-phorbol-13-acetate resulted in delayed and

105 neutrophil adhesion induced by FMLP and 12-O-tetradecanoyl-phorbol-13-acetate to resting and TNF-acti

106 in untreated skin and after short-term 12-O-tetradecanoyl-phorbol-13-acetate treatment and acute UVB

107 irect activation of protein kinase C by 12-O-tetradecanoyl-phorbol-13-acetate was also sufficient to

108 ic-phase infection by the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate was blocked by protein

109 12-O-tetradecanoyl-phorbol-13-acetate was effective in increa

110 ma, exhibit a marked resistance to TPA (12-O-tetradecanoyl-phorbol-13-acetate)-induced keratinocyte p

111 component of K+ current was enhanced by 12-O-tetradecanoyl-phorbol-13-acetate, an activator of PKC, a

112 evident in 7,12-dimethylbenzanthracene/12-O-tetradecanoyl-phorbol-13-acetate-induced tumors from Er/

113 Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-stimulated IL-8 product

114 repeated exposure to the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate.

115 teroid sulfatase inhibitor (p-O-sulfamoyl)-N-tetradecanoyl tyramine (DU-14) could reverse scopolamine

116 teroid sulfatase inhibitor (p-O-sulfamoyl)-N-tetradecanoyl tyramine (DU-14) to rats for 15 days incre

117 cated an IC50 of 38 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MCF-7 cell

118 ated an IC50 of 350 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MDA-MB-231

119 sing regioselective enzymatic acylation with tetradecanoyl vinyl ester to afford 6-O-tetradecanoyl-al